Market Overview

Cerveau Technologies Inc. Announces Expanded Research Access to Novel Tau Imaging Agent


Cerveau Technologies, Inc. today announced expansion of the production
network for its novel tau imaging agent, [18F]MK-6240, an
investigational imaging agent to be used in Positron Emission Tomography
(PET) scans for assessing the status and progression of neurofibrillary
tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are
a hallmark of several neurodegenerative diseases, including Alzheimer's
Disease. This expansion has been driven by the increasing interest in [18F]MK-6240
as a developmental and investigational tool in clinical trials.

In recent weeks, Cerveau has qualified production sites in Hayward, CA;
Houston, TX; Phoenix, AZ; Birmingham, AL; as well as academic sites at
John Hopkins University and Columbia University. These six (6) sites
join an already existing network of ten (10) production sites in the US,
Canada, Australia, and Belgium.

Twenty additional sites in Canada (1), the United States (3) Japan (4),
Australia (4), Europe (4), and China (4) are undergoing capital
expansion, technology transfer and start up processes. These sites will
support a range of research and therapy clinical trial initiatives
globally. This extensive production network will ultimately support
imaging biomarkers licensed by Cerveau and its partners in research and

"Cerveau is focused on increasing access to the transformative
technologies that we believe have the potential to advance brain
health," says Rick Hiatt, President and Chief Executive Officer, Cerveau
Technologies, Inc. "This expansion of the biomarker production network
underscores our commitment to the broader scientific research community
and our support of industry's initiatives to combat neurodegenerative

About Cerveau Technologies, Inc.

Cerveau Technologies, Inc. is a partnership between Enigma Biomedical
Group, Inc. and Sinotau Pharmaceutical Group. Cerveau's vision is to
globally develop diagnostics and technology that positively impact
patients with neurodegenerative disorders including Alzheimer's disease.

View Comments and Join the Discussion!